A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Cytoreductive Stereotactic Body Radiotherapy with Tyrosine Kinase Inhibitors for Intrathoracic Oligoprogressive EGFR-mutated Lung Cancer
[post]
2021
unpublished
Background: Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) shows an impressive initial response to EGFR tyrosine kinase inhibitors (EGFR-TKI). However, resistance invariably develops, commonly involving the site of initial gross disease. Cytoreductive stereotactic body radiotherapy (SBRT) for thoracic oligoprogressive disease (OPD) may effectively delay progression through EGFR-TKI therapy.Methods: From a prospectively maintained IRB-approved institutional
doi:10.21203/rs.3.rs-1132236/v1
fatcat:k364f5djbfaerf6ssmtrwowyea